Navigation Links
'First-in-human' drug for malignant glioma available in experimental trial
Date:2/15/2012

CINCINNATI -- The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

The "first-in-human" phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia.

Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.

The experimental drug (called AMG 595) is intended to target a specific mutated cell receptor (EGFRvIII) which exists on the surface of tumor cells in up to 30 percent of patients with malignant gliomas. Preliminary studies in animals have shown that ADC molecules can effectively find these specific cancer cells, then enter them and release an active cytotoxic agent with the aim of killing the tumor cells while minimizing damage to the surrounding normal tissue.

"This allows us to use a highly cytotoxic drug targeted to the cancer cells in the brain based on a specific cellular marker," explains Rixe, John and Gladys Strauss Chair in Cancer Research at the UC College of Medicine and director of the Experimental Therapeutics/Phase 1 Clinical Trials Program. "Until recently, primary brain tumor patients have traditionally been excluded from phase-1 oncology studies, so finding drugs to effectively target and make real advances against this particular type of very aggressive cancer has been virtually impossible."

Patients who have failed first- and second-line therapies for malignant glioma may qualify to participate in this trial. Potential candidates will be screened for the EGFRvIII mutation using t
'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
2. Using Viagra to combat malignant melanoma
3. Elusive gene mutations found for malignant brain tumor
4. Agent selectively targets malignant B cells in chronic leukemia, study shows
5. Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable
6. Huge pelvi-abdominal malignant inflammatory myofibroblastic tumor
7. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
8. CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
9. RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
10. Photons vs. protons for treatment of spinal cord gliomas
11. Discordance among commercially-available diagnostics for latent TB infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... gas prices rose in recent years, so did motorcyclist ... times of gas increases, more people start using motorcycles ... explained. They examined data gathered between 2002 and ... motorcycle registrations in the United States and the third ... a strong association between rising gas prices and an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
(Date:12/15/2014)... CITY, NV (PRWEB) December 15, 2014 ... powerhouse company, JM Ocean Avenue. JM Ocean Avenue ... of the Veretekk online automated marketing system. JM ... the June 2014 merger of Ocean Avenue and JM ... more than $2 Billion per year company. , “After ...
(Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... pain caused by osteoarthritis , , THURSDAY, Nov. 8 (HealthDay News) ... sufferers, a preliminary study found. , "We don,t recommend people ... study author Dr. Jasvinder Singh, a staff physician at the ... and more patients needed to be assessed before the treatment ...
... have discovered that a molecular switch in the protein making ... common forms of lethal breast cancer worldwide. The discovery by ... therapies for the cancer, called locally advanced breast cancer (LABC)., ... LABC may account for 50 percent or more of breast ...
... in annual ,America,s Best,Health Plans, issue, ATLANTA, Nov. 8 ... placed Kaiser Permanente of Georgia first in,the state for the ... The magazine, on newsstands Nov. 5, 2007, also ranked Kaiser,Permanente,s ... the top,Medicare plan in the state for 2007 and one ...
... WEST BRIDGEWATER, Mass., Nov. 8 Pressure,BioSciences, Inc. (Nasdaq: ... host,a teleconference to discuss its third quarter financial results ... to the,teleconference either by telephone or through a live ... Date: Monday, November 12, 2007 Time: 4:30 p.m. ...
... Matthew Gregory, the Washington,state man who,s spent more than ... Research Center, expects to conclude his odyssey,today at the southernmost ... Sept. 1, 2006, Gregory set out from his home near ... and quit his job,with a beverage distributor to accommodate his ...
... a business integration,provider focused exclusively on health ... has purchased HealthASPex (HAX) through an,asset sale. ... PPO routing,services to Third Party Administrators (TPAs) ... http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) "Tela,s streamlined front-end service ...
Cached Medicine News:Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:A molecular switch is linked to a common breast cancer 2Health News:U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia 2Health News:Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update 2Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2
(Date:12/15/2014)... , Dec. 15, 2014  Colorado and ... have legalized adult use of cannabis. Oregon ... D.C. ended prohibition during the November 2014 elections. ... Photo - http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits ... noted and obvious benefits like the increased tax revenue for ...
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
Breaking Medicine Technology:CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... ( US HIFU ), a world leader in minimally invasive ... ) technologies and manufacturer of the Sonablate® 500 medical device ... available to prostate cancer patients for the first ... Curitiba, capital city of the state of Parana in southern ...
... Medical, Inc. ("Kips Bay"), a development stage medical device ... vein support technology, or eSVS MESH, for use in ... it has closed its previously announced offering of 2,062,500 ... $8.00 per share.   Kips Bay ...
Cached Medicine Technology:Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 2Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 3Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 4Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock 2
This cannula is flanged with radiopaque tip with 2 side holes....
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
The DLP Elongated One-Piece Arterial Cannulae features a longer body for easier access during conventional and minimally invasive procedures...
Medicine Products: